RT Journal Article SR Electronic T1 EP773 Splenectomy as primary cytoreductive surgery in advanced stage epithelial ovarian cancer JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP A429 OP A430 DO 10.1136/ijgc-2019-ESGO.824 VO 29 IS Suppl 4 A1 H Akilli A1 L Aksoy Karakaş A1 H Nihan A1 A Ayhan YR 2019 UL http://ijgc.bmj.com/content/29/Suppl_4/A429.3.abstract AB Introduction/Background The aim of the study was to evaluate site of splenic metastases and ıts affect on survival in advanced stage epithelial ovarian cancer.Methodology This retrospective study was done in Baskent University School of Medicine, Ankara, Turkey. We evaluated 182 patients who underwent splenectomy as a part of primary cytoreductive surgery between 2008–2018 Besides we invastegated 2,3 and 5 year overall survival rates.Results Median age was 61 years (27–81),Median lenght of stay was 13 days (4–87 days). 40 (21,7%) patients had paranchimal and 144 (78,3%) had non paranchimal (Hilar or capsular) metastases,Median overal survival was 27 months and 31 months respectively(p=0,6).Conclusion Splenectomy in primary cytoreductive surgery is an effective intervention to achive R0 resection in advanced stage EOC However site of splenic metastases has no impact on short term and long term overall survival.Disclosure Nothing to disclose.View this table:Abstract EP773 Table 1 Median Overall Survival rates According to site of Splenic Metastases